03:13 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Amgen's Repatha lowers LDL-C in Phase III for dyslipidemia in Type II diabetics

Amgen Inc. (NASDAQ:AMGN) reported in June that Repatha evolocumab met the co-primary endpoints in the Phase III BANTING trial to treat hypercholesterolemia or mixed dyslipidemia in Type II diabetics taking the maximum tolerated dose of...
20:46 , Aug 13, 2018 |  BC Extra  |  Preclinical News

Polygenic scores increase disease risk prediction

Two studies in Nature Genetics suggest that aggregating SNPs, instead of assessing single SNPs, to generate risk scores from genome-wide association studies (GWAS) could improve predictions for disease risk. The use of individual gene variants identified...
00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

RegenxBio discloses second serious AE for hypercholesterolemia gene therapy

RegenxBio Inc. (NASDAQ:RGNX) said RGX-501 led to a second treatment-related serious adverse event in a Phase I/II trial to treat homozygous familial hypercholesterolemia (HoFH). The open-label, international trial has enrolled six patients to receive a single...
00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The authors...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Ironwood reports Phase IIb data of praliciguat to treat diabetes with hypertension

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported data from 26 diabetic patients with hypertension in a Phase IIa study showing that compared with placebo praliciguat (IW-1973) reduced blood pressure (6.3 vs. 1.5 mmHg), fasting glucose levels (32.5...
16:48 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Gemphire's gemcabene meets in Phase IIb for severe hypertriglyceridemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported data from the Phase IIb INDIGO-1 trial to treat severe hypertriglyceridemia showing that once-daily 600 mg oral gemcabene (CI-1027) met the primary endpoint of reducing median triglycerides from baseline to...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
16:34 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY OUTCOMES trial showing that Praluent alirocumab given on top of statins lowered the risk of major adverse cardiovascular events...
14:36 , Mar 10, 2018 |  BC Extra  |  Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Armed with cardiovascular outcomes data for Praluent alirocumab and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have a proposition for payers:...
15:21 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Ionis' Akcea reports Phase I/IIa data for AKCEA-APOCIII-LRx in hypertriglyceridemia

In October, Akcea Therapeutics Inc. (NASDAQ:AKCA) reported data from a Phase I/IIa trial in about 56 healthy volunteers and patients with hypertriglyceridemia showing that AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) led to reductions in apolipoprotein C-III (APOCIII; APOC3) protein...